GlyTherix Ltd is one of 25 Australian life science companies presenting new business opportunities to international investors during the Asian investment series, hosted by AusBiotech. The events are on 26 March in Hong Kong and 28-29 March in Shanghai and will attract more than 150 investors. 

Minomic’s CEO, Dr Brad Walsh, said, “The event will provide an excellent opportunity for GlyTherix Ltd to present the company’s novel anti-cancer therapy. ”